Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation (Q39096573)

9 September 2017

Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation (English)

1 reference

9 September 2017

1 reference

Dan-feng Sun

1

1 reference

9 September 2017

Yan-jie Zhang

2

1 reference

9 September 2017

Xiao-qing Tian

3

1 reference

9 September 2017

Ying-xuan Chen

4

1 reference

9 September 2017

Jing-yuan Fang

5

1 reference

9 September 2017

language of work or name

1 reference

10 October 2013

1 reference

Cell Biology International

9 September 2017

1 reference

9 September 2017

38

1 reference

9 September 2017

1

1 reference

9 September 2017

50-63

1 reference

Identification of TOR signaling complexes: more TORC for the cell growth engine

9 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

mTOR as a therapeutic target in patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Roles of cell division and gene transcription in the methylation of CpG islands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Epigenetic epidemiology for cancer risk: harnessing germline epigenetic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

LY294002 and rapamycin co-operate to inhibit T-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Role of Akt/protein kinase B in the activity of transcriptional coactivator p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Role of epigenetics in cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Cancer epigenetics: from mechanism to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Effects of histone acetylation and DNA methylation on p21( WAF1) regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Epigenetic mechanisms in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Optimal locoregional treatment in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Histone modifications and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

The role of epigenetics in environmental and occupational carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

Relevance of cyclin D1 level in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIN.10179

21 January 2018

Identifiers

DOI

10.1002/CBIN.10179

1 reference

9 September 2017

1 reference